Humate(HUMA), even with sales of $2 million, secures a U.S. Department of Defense and Saudi Arabia contract... Commercialization "green light"

Humacyte (HUMA) is still in the early stages of commercialization, but it has achieved meaningful results in both global market expansion and clinical progress, reaffirming the growth potential of its “bioengineered vascular” business. Particularly, the combination of support from the U.S. Department of Defense and results from entering the Middle Eastern market has enhanced expectations for future sales expansion.

Humacyte announced that sales for the fourth quarter of 2025 will be $500,000, with annual sales reaching $2 million. Among these, sales of the core product “Symvess” amounted to $400,000 in the fourth quarter and $1.4 million for the year. Although still in the early sales stage with limited sales volume, the continuous reordering by actual hospitals indicates that a demand base is forming.

Global expansion has also officially launched. The company has secured a purchase commitment of at least $1.475 million (approximately 21.2 billion Korean won) in Saudi Arabia. This contract includes local hospital evaluation programs and surgeon training, and is expected to serve as a foothold for entering the Middle Eastern market. Additionally, the company has submitted a sales license application to the Israeli Ministry of Health and is rapidly advancing its overseas commercialization strategy.

Domestically in the U.S., the company has received support for introducing bioengineered vascular technology through the defense budget under the “Trump Administration.” The U.S. Department of Defense has allocated relevant budgets to ensure the technology for treating military personnel suffering from traumatic vascular injuries, and Humacyte is collaborating with the military and the Department of Defense to expand the supply of Symvess. This goes beyond mere sales and is significant in securing government-level demand.

The product’s competitiveness has also been supported by clinical data. Tracking results of up to 36 months show that Symvess maintains a low infection rate and high vascular patency rate; in studies involving wartime injured patients from Ukraine, a patency rate of 87.1% and a limb preservation rate of 100% were recorded. The industry is paying attention to this data validated in actual battlefield conditions.

The core pipeline “ATEV” is also facing an important watershed. Interim results from the phase 3 trial (V012) for patients undergoing hemodialysis are expected to be published in the second quarter of 2026, and based on the results, a Biologics License Application (BLA) will be advanced in the second half of the year. In previous clinical trials, this product has proven to extend the usage period by up to 6 months compared to existing autologous vessels, demonstrating competitiveness.

There are signs of structural improvement in the financial aspect. The annual net loss was $40.8 million (approximately 587 billion Korean won), significantly reduced from the previous year, reflecting decreased R&D expenses and gains from fair value assessments. However, with approximately $9.7 million in cost of goods sold included, the cost burden during the early commercialization process still exists. The company holds about $50.5 million in cash and has enhanced liquidity through additional financing and obtaining a credit line of up to $77.5 million.

Industry evaluations suggest that Humacyte is following the typical path of an “early-stage biotechnology company.” Analysts point out that although initial sales are insignificant, the combination of government demand, overseas expansion, and clinical results is forming a foundation for medium- to long-term growth.

Comment: Although it has not yet reached the stage of ensuring profitability, the support from the U.S. Department of Defense and the Middle Eastern contract are interpreted as signals that the market is materializing faster than expected. Future clinical trial results are expected to be a key watershed for the company’s value.